• Taltirelin Acetate Research Workflows

  2026-09-29

  Taltirelin acetate supports integrated workflows spanning dopaminergic motor assays, cellular neuroprotection, itch studies, sleep research, and oral formulation development. Its long-acting TRH-receptor pharmacology is especially useful when sustained pathway modulation must be distinguished from the rapid dopamine fluctuations associated with conventional replacement strategies.

• Alcian Blue & Nuclear Fast Red in Translation

  2026-09-29

  A translational framework for using dual staining to connect acid mucin biology, chondrogenic differentiation, and tissue-level evidence without confusing endpoint histochemistry with specimen tracking.

• Rucaparib Workflows for DNA Damage Research

  2026-09-28

  Rucaparib (AG-014699) provides a practical way to connect PARP1 inhibition with persistent DNA-break signaling, radiosensitization, and repair-defect biology. This workflow-focused guide covers dosing design, γ-H2AX and p53BP1 assays, transporter-aware interpretation, and how the latest RNA Pol II apoptosis findings can refine mechanistic controls.

• Lipo3K Transfection Reagent for ASO Assays

  2026-09-28

  Build a practical workflow for screening nucleic-acid delivery in cancer-cell assays, from plasmid controls to RNA interference readouts. Lipo3K Transfection Reagent offers a low-cytotoxicity option for comparing delivery conditions, while pH-responsive ASO designs require their own structural and functional validation.

• Designing Clickable PEG-Lipids for RNA Delivery

  2026-09-27

  DMG-PEG2000-N3 offers a modular azide handle for bioconjugation. This article examines how translational teams can evaluate PEG-lipid chemistry alongside lipid nanoparticle performance and emerging drying strategies—without confusing a useful design option with a clinically validated formulation.

• Naloxone Hydrochloride: Research Mechanisms

  2026-09-26

  Naloxone hydrochloride is a potent opioid receptor antagonist for studying opioid-receptor signaling and related biological responses. Product information also describes neural stem cell proliferation modulation through a TET1-dependent, receptor-independent mechanism, which should be tested separately from receptor blockade.

• Alcian Blue & Nuclear Fast Red Staining Kit: Readout

  2026-09-25

  The Alcian Blue & Nuclear Fast Red Staining Kit pH2.5 visualizes acidic mucosubstances while preserving nuclear context. This article distinguishes phenotype staining from small-biopsy tissue marking and explains what the evidence does—and does not—support.

• Alcian Blue & Nuclear Fast Red Staining Kit Guide

  2026-09-25

  This dual stain helps researchers visualize acidic mucosubstances in tissue sections and assess matrix-rich chondrogenic cultures, with red nuclear contrast to aid morphology review. A small-biopsy study also offers a useful caution: Alcian blue can make tiny samples easier to see during processing, but that tissue-marking use is distinct from validated histochemical staining.

• Gastric Cancer Assembloids Capture Tumor–Stroma Effects

  2026-09-24

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with stromal subpopulations from matched tissue. Their findings show that stromal cells can reshape gene-expression profiles and alter drug sensitivity, underscoring the value of tumor–microenvironment models for preclinical and personalized therapy research.

• PXDN–LDHA Signaling Drives Glioblastoma Glycolysis

  2026-09-24

  A 2026 study identifies peroxidasin (PXDN) as a candidate regulator of glioblastoma glycolysis and links its effects on malignant cell behavior to lactate dehydrogenase A (LDHA). Its knockdown and LDHA-rescue experiments support a functional PXDN–LDHA pathway, while the computational and preclinical evidence leaves clinical validation as a key next step.

• Ridaforolimus in mTOR Assay Workflows

  2026-09-23

  Use Ridaforolimus to test whether mTOR suppression changes cancer-cell signaling, growth, or VEGF output—with dose and time points that support follow-up assays. A separate machine-learning senolytic study offers a useful screening-design lesson, but does not establish Ridaforolimus as a senolytic.

• Lipo3K Transfection Reagent: Practical Guide

  2026-09-23

  Learn how to use Lipo3K Transfection Reagent for plasmid DNA, siRNA, mRNA, and challenging cell models while preserving cell health and assay reproducibility. This guide translates a pH-responsive antisense oligonucleotide study into practical delivery, optimization, and troubleshooting decisions.

• From Acid Mucin Signal to Translational Evidence

  2026-09-22

  A mechanistic and strategic guide to using the Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5 for acid mucin visualization, chondrogenic differentiation staining, and better translational decision-making.

• IGF2BP3–FZD1/7 Drives Carboplatin Resistance

  2026-09-22

  This 2025 Cancer Letters study identifies an IGF2BP3–FZD1/7 regulatory axis that maintains stem-like properties and carboplatin resistance in triple-negative breast cancer. Its findings connect m6A-dependent RNA stabilization, β-catenin signaling, and homologous recombination repair, while supporting FZD1/7 inhibition as a strategy for sensitizing TNBC cancer stem-like cells.

• Masitinib (AB1010) KIT/PDGFR Workflow Guide

  2026-09-21

  Masitinib (AB1010) provides a DMSO-compatible research reagent for studying KIT and PDGFRα/β signaling, including cancer biology, mastocytosis research, and inflammatory cell models. It should not be treated as a clinical treatment recommendation or used in workflows requiring aqueous or ethanol solubility without additional formulation validation.

667 records 1/45 page Next 12345 下5页 Last page